Form 4: Inmune Bio CFO David Moss Acquires 223,000 Stock Options

Inmune Bio's Chief Financial Officer, David Moss, was granted 223,000 stock options on December 5, 2024, which will vest in two years.

Summary

• David Moss, the Chief Financial Officer of Inmune Bio, Inc., was granted 223,000 stock options on December 5, 2024.
• These options have an exercise price of $5.05 per share.
• The options will become fully vested and exercisable on December 5, 2026, which is the two-year anniversary of the grant date.
• The options were granted under the company's 2021 Stock Incentive Plan.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting period of two years encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with the company's long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech sector.
• The vesting period of two years is also typical, designed to encourage long-term commitment and performance.
• The exercise price of $5.05 is a standard feature of stock options, allowing the executive to purchase shares at a predetermined price.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to work towards increasing the company's value.
• The grant does not have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

stock options, insider trading, executive compensation, Inmune Bio, David Moss, equity